Investing.com -- AbbVie Inc. (NYSE: ABBV) reported first-quarter results that exceeded Wall Street expectations, sending shares higher in premarket trading.

Adjusted earnings per share came in at $2.65, beating the analyst consensus of $2.59 by $0.06. Revenue reached $15.0 billion, surpassing the estimate of $14.73 billion and representing a 12.4% increase from the prior year period.

The company's immunology portfolio drove growth, generating $7.29 billion in revenue, up 16.4% YoY. Skyrizi led the portfolio with $4.48 billion in sales, up 30.9%, while Rinvoq contributed $2.12 billion, up 23.3%. The neuroscience portfolio posted $2.88 billion in revenue, a 26.0% increase, with Vraylar generating $905 million and Botox Therapeutic reaching $1.01 billion. Shares rose 2.5% following the announcement.

"We are off to an excellent start in 2026, with first-quarter results exceeding our expectations," said Robert A. Michael, chairman and chief executive officer. "AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook."

AbbVie raised its full-year 2026 adjusted diluted EPS guidance to a range of $14.08 to $14.28, up from the previous range of $13.96 to $14.16. The midpoint of $14.18 falls slightly below the analyst consensus of $14.21. The guidance includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred in the first quarter.

The oncology portfolio generated $1.63 billion, essentially flat YoY, with Venclexta contributing $770 million and Imbruvica adding $556 million. The aesthetics portfolio posted $1.19 billion in revenue, up 7.6%, driven by Botox Cosmetic at $668 million and Juvederm at $232 million.